Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$22.3M |
| 2 |
Vontier
VNT
|
+$21.7M |
| 3 |
SS&C Technologies
SSNC
|
+$21.3M |
| 4 |
IPG Photonics
IPGP
|
+$21.3M |
| 5 |
Booking.com
BKNG
|
+$20.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$17.9M |
| 2 |
IS
ironSource Ltd.
IS
|
+$17.2M |
| 3 |
Reinsurance Group of America
RGA
|
+$16M |
| 4 |
VMW
VMware, Inc
VMW
|
+$15.3M |
| 5 |
Belden
BDC
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.14% |
| 2 | Consumer Discretionary | 16.46% |
| 3 | Communication Services | 11.87% |
| 4 | Industrials | 9.35% |
| 5 | Healthcare | 9.2% |
Similar funds
Invenomic Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Invenomic Capital Management held 205 positions worth $1.16B, down 17% from $1.41B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Invenomic Capital Management withdrew a net $108M in Q3 2022, closing 59 positions and reducing 52 holdings. Its most notable exit was Cardinal Health, an estimated $17.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, Invenomic Capital Management opened a new position in Zoom worth $17.2M.
- Invenomic Capital Management's largest Q3 2022 buy was Zoom: 234,351 shares worth $17.2M.
- Invenomic Capital Management added most to IPG Photonics in Q3 2022, an estimated $21.3M increase.
- Invenomic Capital Management's biggest Q3 2022 reduction was Belden, cutting an estimated $13.5M.
- Invenomic Capital Management fully exited Cardinal Health in Q3 2022, selling an estimated $17.9M.
- Invenomic Capital Management's ten largest holdings make up 23% of its $1.16B portfolio in Q3 2022.
- Invenomic Capital Management opened 58 new positions and closed 59 in Q3 2022.
- Invenomic Capital Management's portfolio value fell 17% quarter-over-quarter to $1.16B.
Based on Invenomic Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.